These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31702945)

  • 1. Application of the New Process for Unapproved Drug Use: Dilemma of Universal Health Care Coverage in Japan.
    Nishiwaki S; Ando Y
    J Glob Oncol; 2019 Nov; 5():1-3. PubMed ID: 31702945
    [No Abstract]   [Full Text] [Related]  

  • 2. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications.
    Shimazawa R; Ikeda M
    Clin Ther; 2012 Oct; 34(10):2104-16. PubMed ID: 23036337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of drug-approval regulations for medical countermeasures against CBRN agents in Japan.
    Shimazawa R; Ikeda M
    Health Secur; 2015; 13(2):130-8. PubMed ID: 25813978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Universal Health Coverage and Primary Healthcare: Lessons From Japan Comment on "Achieving Universal Health Coverage by Focusing on Primary Care in Japan: Lessons for Low- and Middle-Income Countries".
    Bloom G
    Int J Health Policy Manag; 2017 Apr; 6(4):229-231. PubMed ID: 28812806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquisition of expanded indications for intravenous cyclophosphamide in the management of childhood rheumatic disease in general.
    Mori M; Murata T; Takei S; Imagawa T; Yokota S
    Mod Rheumatol; 2011 Oct; 21(5):449-57. PubMed ID: 21499682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unapproved Ophthalmic Drugs.
    Novack GD
    Ocul Surf; 2016 Apr; 14(2):317-20. PubMed ID: 27107659
    [No Abstract]   [Full Text] [Related]  

  • 7. When should insurers cover off-label drug usage?
    Butcher L
    Manag Care; 2009 May; 18(5):40-2. PubMed ID: 19526933
    [No Abstract]   [Full Text] [Related]  

  • 8. Surgery as a component of universal healthcare: Where is South Africa?
    Reddy CL; Makasa EM; Biccard B; Smith M; Steyn E; Fieggen G; Maswime S; Meara JG; Chu K
    S Afr Med J; 2019 Aug; 109(9):624-625. PubMed ID: 31635583
    [No Abstract]   [Full Text] [Related]  

  • 9. Unlicensed and off-label drug use in an Irish neonatal intensive care unit: a prospective cohort study.
    Kieran EA; O'Callaghan N; O'Donnell CP
    Acta Paediatr; 2014 Apr; 103(4):e139-42. PubMed ID: 24397831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controversies in off-label prescriptions in dermatology: the perspective of the patient, the physician, and the pharmaceutical companies.
    França K; Litewka S
    Int J Dermatol; 2019 Jul; 58(7):788-794. PubMed ID: 30168846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Company pays over $81m for allegedly promoting topiramate for unapproved uses.
    Kmietowicz Z
    BMJ; 2010 May; 340():c2848. PubMed ID: 20508021
    [No Abstract]   [Full Text] [Related]  

  • 12. [Off-label use of drugs--the legal framework].
    Koyuncu A
    Dtsch Med Wochenschr; 2012 Jul; 137(30):1519-23. PubMed ID: 22869512
    [No Abstract]   [Full Text] [Related]  

  • 13. A systematic review of the health-financing mechanisms in the Association of Southeast Asian Nations countries and the People's Republic of China: Lessons for the move towards universal health coverage.
    Myint CY; Pavlova M; Thein KN; Groot W
    PLoS One; 2019; 14(6):e0217278. PubMed ID: 31199815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Japan works to shorten "drug lag," boost trials of new drugs.
    Sinha G
    J Natl Cancer Inst; 2010 Feb; 102(3):148-51. PubMed ID: 20107160
    [No Abstract]   [Full Text] [Related]  

  • 15. Achieving Universal Health Coverage by Focusing on Primary Care in Japan: Lessons for Low- and Middle-Income Countries.
    Ikegami N
    Int J Health Policy Manag; 2016 Feb; 5(5):291-3. PubMed ID: 27239877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off-label medication use.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2012 Sep; 50(9):11-3. PubMed ID: 22897212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric off-label use of psychotropic drugs approved for adult use in Japan in the light of approval information regarding pediatric patients in the United States: a study of a pharmacy prescription database.
    Tanemura N; Asawa M; Kuroda M; Sasaki T; Iwane Y; Urushihara H
    World J Pediatr; 2019 Feb; 15(1):92-99. PubMed ID: 30506238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unapproved prescription cough, cold, and allergy drug products: recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications.
    Ostroff C; Lee CE; McMeekin J
    Chest; 2011 Aug; 140(2):295-300. PubMed ID: 21813527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical review of the determination process by the Japanese reviewing authority in approving the additional efficacy of fludarabine phosphate.
    Narimatsu H; Oiso G; Ono S; Kami M
    J Clin Oncol; 2009 Dec; 27(34):e236-8. PubMed ID: 19884538
    [No Abstract]   [Full Text] [Related]  

  • 20. Japan: achieving UHC by regulating payment.
    Ikegami N
    Global Health; 2019 Nov; 15(Suppl 1):72. PubMed ID: 31775796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.